Annual Review of Pathology Mechanisms of Disease,
Journal Year:
2018,
Volume and Issue:
13(1), P. 395 - 412
Published: Jan. 24, 2018
Metastasis
is
the
major
cause
of
cancer-related
deaths;
therefore,
prevention
and
treatment
metastasis
are
fundamental
to
improving
clinical
outcomes.
Epithelial
mesenchymal
transition
(EMT),
an
evolutionarily
conserved
developmental
program,
has
been
implicated
in
carcinogenesis
confers
metastatic
properties
upon
cancer
cells
by
enhancing
mobility,
invasion,
resistance
apoptotic
stimuli.
Furthermore,
EMT-derived
tumor
acquire
stem
cell
exhibit
marked
therapeutic
resistance.
Given
these
attributes,
complex
biological
process
EMT
heralded
as
a
key
hallmark
carcinogenesis,
targeting
pathways
constitutes
attractive
strategy
for
treatment.
However,
demonstrating
necessity
vivo
technically
challenging,
recent
efforts
demonstrate
functional
contribution
have
yielded
unexpected
results.
Therefore,
determining
role
remains
area
active
investigation.
Studies
using
improved
lineage
tracing
systems,
dynamic
imaging,
clinically
relevant
models
potential
uncover
direct
link
between
metastasis.
This
review
focuses
primarily
on
advances
emerging
concepts
biology
discusses
future
directions
context
novel
diagnostic
opportunities.
Science,
Journal Year:
2015,
Volume and Issue:
348(6230), P. 74 - 80
Published: April 2, 2015
Effective
immunotherapy
promotes
the
killing
of
cancer
cells
by
cytotoxic
T
cells.
This
requires
not
only
that
cancer-specific
be
generated,
but
also
these
physically
contact
The
coexistence
in
some
patients
and
recognize
them
indicates
tumors
may
exhibit
phenomenon
immune
privilege,
which
immunogenic
tissue
is
protected
from
attack.
Here,
we
review
evidence
stromal
tumor
microenvironment
mediate
this
restriction
excluding
vicinity
Overcoming
cell
checkpoint
thus
enable
optimal
immunotherapy.
Blood Cancer Journal,
Journal Year:
2021,
Volume and Issue:
11(4)
Published: April 6, 2021
Abstract
Chimeric
antigen
receptor
(CAR)-T
cell
therapy
is
a
revolutionary
new
pillar
in
cancer
treatment.
Although
treatment
with
CAR-T
cells
has
produced
remarkable
clinical
responses
certain
subsets
of
B
leukemia
or
lymphoma,
many
challenges
limit
the
therapeutic
efficacy
solid
tumors
and
hematological
malignancies.
Barriers
to
effective
include
severe
life-threatening
toxicities,
modest
anti-tumor
activity,
escape,
restricted
trafficking,
limited
tumor
infiltration.
In
addition,
host
microenvironment
interactions
critically
alter
function.
Furthermore,
complex
workforce
required
develop
implement
these
treatments.
order
overcome
significant
challenges,
innovative
strategies
approaches
engineer
more
powerful
improved
activity
decreased
toxicity
are
necessary.
this
review,
we
discuss
recent
innovations
engineering
improve
both
malignancy
limitations
tumors.
